The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
Open accessAbstract
We examined the effect of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen-specific T-cell responses in patients with multiple sclerosis (MS). Glatiramer acetate (Copaxone) functioned as a universal antigen, inducing proliferation, independent of any prior exposure to the polymer, in T-cell lines prepared from MS or healthy subjects. However, for most patients, daily injections of glatiramer acetate abolished this T-cell response and promoted the secretion of IL-5 and IL-13, which are characteristic of Th2 cells. The surviving glatiramer acetate-reactive T cells exhibited a greater degree of degeneracy as measured by cross-reactive responses to combinatorial peptide libraries. Thus, it appears that, in some individuals, in vivo administration of glatiramer acetate induces highly cross-reactive T cells that secrete Th2 cytokines. To our knowledge, glatiramer acetate is the first agent that suppresses human autoimmune disease and alters immune function by engaging the T-cell receptor. This compound may be useful in a variety of autoimmune disorders in which immune deviation to a Th2 type of response is desirable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis
Chen, Y., Kuchroo, V. K., Inobe, J.-I., Hafler, D. A., & Weiner, H. L. (1994) · Science · doi:10.1126/science.7520605 · Cited by 1,973
Self-citationJohnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
Lehmann, P. V., Forsthuber, T., Miller, A., & Sercarz, E. E. (1992) · Nature · doi:10.1038/358155a0 · Cited by 1,186
Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
Sloan-Lancaster, J., Evavold, B. D., & Allen, P. M. (1993) · Nature · doi:10.1038/363156a0 · Cited by 587
Separation of IL-4 Production from Th Cell Proliferation by an Altered T Cell Receptor Ligand
Evavold, B. D., & Allen, P. M. (1991) · Science · doi:10.1126/science.1833816 · Cited by 549
Zhang, J., Markovic-Plese, S., Lacet, B., Raus, J., Weiner, H. L., & Hafler, D. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.973 · Cited by 529
Self-citationT Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis
Critchfield, J. M., Racke, M. K., Zúñiga-Pflücker, J. C., Cannella, B., Raine, C. S., Goverman, J., & Lenardo, M. J. (1994) · Science · doi:10.1126/science.7509084 · Cited by 524
Mapping T-cell receptor–peptide contacts by variant peptide immunization of single-chain transgenics
Jorgensen, J. L., Esser, U., Fazekas de St. Groth, B., Reay, P. A., & Davis, M. M. (1992) · Nature · doi:10.1038/355224a0 · Cited by 516
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
Fukaura, H., Kent, S. C., Pietrusewicz, M. J., Khoury, S. J., Weiner, H. L., & Hafler, D. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118779 · Cited by 473
Self-citation
Cited by
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,042
Gold, R. (2006) · Brain · doi:10.1093/brain/awl075 · Cited by 1,017
“Besides its immunological actions (Duda et al., 2000), glatiramer acetate may also act through neuroprotection by stimulating BDNF secretion [reviewed in Hohlfeld et al. (2000)].”
BackgroundComi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L., Comi, G., Kappos, L., Oger, J., et al. (2000) · Nature Medicine · doi:10.1038/80525 · Cited by 512
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
Treatment of multiple sclerosis with the pregnancy hormone estriol
Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C. J., & Voskuhl, R. R. (2002) · Annals of Neurology · doi:10.1002/ana.10301 · Cited by 435
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite
Platten, M., Ho, P. P., Youssef, S., Fontoura, P., Garren, H., Hur, E. M., Gupta, R., Lee, L. Y., Kidd, B. A., Robinson, W. H., et al. (2005) · Science · doi:10.1126/science.1117634 · Cited by 425
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Butovsky, O., Koronyo-Hamaoui, M., Kunis, G., Ophir, E., Landa, G., Cohen, H., & Schwartz, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604681103 · Cited by 388
Peptide-based therapeutic vaccines for allergic and autoimmune diseases
Larché, M., & Wraith, D. C. (2005) · Nature Medicine · doi:10.1038/nm1226 · Cited by 326
Hafler, D. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21357 · Cited by 315
Self-citationThe role of TH17 cells in multiple sclerosis: Therapeutic implications
Moser, T., Akgün, K., Proschmann, U., Sellner, J., & Ziemssen, T. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102647 · Cited by 302
Ziemssen, T. (2002) · Brain · doi:10.1093/brain/awf252 · Cited by 268
Hong, J., Li, N., Zhang, X., Zheng, B., & Zhang, J. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502187102 · Cited by 264
Inhibition of Human CD4+CD25+high Regulatory T Cell Function
Baecher-Allan, C., Viglietta, V., & Hafler, D. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6210 · Cited by 262
Self-citationButovsky, O. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26836 · Cited by 261
Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C., De Jager, P., & Baecher‐Allan, C. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00240.x · Cited by 260
Self-citationAppel, S. H., Beers, D. R., & Henkel, J. S. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.09.003 · Cited by 256
“GA is classically used in the treatment of multiple sclerosis (MS) where it has been documented to induce Th2-polarized immune responses which may mediate neuroprotection through the release of IL-4, suppressing the production and release of free radicals from activated microglia [42,43].”
BackgroundGlatiramer acetate: Mechanisms of action in multiple sclerosis
Schrempf, W., & Ziemssen, T. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.003 · Cited by 168
Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen, T., & Schrempf, W. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79024-4 · Cited by 135
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Metadata
- Authors
- Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-04-01
- Volume
- 105
- Issue
- 7
- Pages
- 967-976
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2171907184
- Cited by
- 416
- References
- 34
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.